Live tape
Top 8, mentions 7d5,443GOOGL1,027 mentions▲ +0.04ORCL866 mentions▲ +0.04NVDA747 mentions▲ +0.07AAPL721 mentions▲ +0.07META592 mentions▲ +0.05SPY538 mentions▲ +0.06QQQ500 mentions▲ +0.08TSLA452 mentions▲ +0.07

Equity · Healthcare

BMRN

BioMarin Pharmaceutical Inc. · NasdaqGS

$64 −3.67% 1D Finazon · prior-day close · Sep 15, 2026
Price · Chart
Our own end-of-day closes 61 sessions
$80 $50 18 Jun 15 Sep

The line runs $55 on 18 June through $64 on 15 September, on a scale from $50 to $80. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of BMRN over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $55 on 18 June 2026 through $64 on 15 September 2026.

Market cap $12.4B
P/E (TTM) 34.8
52-week range $49.67 – $70.23
Avg volume 194.4K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 16, 2026

BMRN insider trades

SEC Form 4 · last 90 days · newest reported trade 2 Sep 2026
Open-market buys 0
Open-market sells 1
Net sold $1.16M
Non-trade filings 1
Date Insider Type Shares Value
02 Sep 2026 Davis George Eric EVP, Chief Legal Officer Sell 17,557 $1.16M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
10 Sep 2026 Plenge Robert M Director Award 6,140

BMRN reported financials

SEC EDGAR XBRL

BMRN reported revenue of $3.2B for the fiscal year ended 31 Dec 2025. Net income over the same period was $348.9M.

Figure Reported Period
Revenue $3.2B 31 Dec 2025 fiscal year
Net income $348.9M 31 Dec 2025 fiscal year
Diluted EPS $1.80 31 Dec 2025 fiscal year
Total assets $11.7B 30 Jun 2026 at period end
Total equity $6.3B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

BMRN earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.23 —
31 Mar 2026 Q1 2026 $0.54 —
31 Dec 2025 FY 2025 $1.80 —
30 Sep 2025 Q3 2025 $-0.16 —
30 Jun 2025 Q2 2025 $1.23 —
31 Mar 2025 Q1 2025 $0.95 —
31 Dec 2024 FY 2024 $2.21 —
30 Sep 2024 Q3 2024 $0.55 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

BMRN institutional holders

SEC Form 13F

13 of the 45 institutional funds we track reported a BMRN position for the quarter ended 30 Jun 2026 — a combined $1.1B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Viking Global Investors Held (±25%) +7.9% shares 7,616,563 $435.8M
AQR Capital Management Trimmed −25.8% shares 5,699,541 $322.5M
Millennium Management Trimmed −31.2% shares 2,071,816 $118.5M
Citadel Advisors Trimmed −75.1% shares 1,122,408 $64.2M
Balyasny Asset Management Held (±25%) −22.6% shares 1,054,613 $60.3M
Renaissance Technologies Trimmed −55.9% shares 451,871 $25.9M
Man Group Held (±25%) +18.8% shares 367,981 $21.1M
Bridgewater Associates Added +32.9% shares 274,911 $15.7M
Marshall Wace New position 97,300 $5.6M
D. E. Shaw & Co. Trimmed −67.4% shares 92,214 $5.3M

Showing the 10 largest of 13 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

BMRN fails-to-deliver

SEC CNS data

On 24 Aug 2026, 260 shares of BMRN failed to deliver (about $17K).

Settlement date Shares failed Notional % of shares out
24 Aug 2026 260 $17K <0.001%
11 Aug 2026 5,650 $389K 0.003%
07 Aug 2026 29,279 $1.8M 0.015%
04 Aug 2026 97 $6K <0.001%

Source: SEC fails-to-deliver (CNS) data